Recent Updates
Recently added Catalysts
AGEN Negative Sentiment Score: 20/100

AGENUS INC. (NASDAQ: AGEN) DEADLINE ALERT: Bernstein Liebhard LLP Reminds Agenus Inc. Investors of Upcoming Deadline

Key Takeaway: Bernstein Liebhard LLP is reminding investors of Agenus Inc. of an upcoming deadline related to a class action lawsuit alleging securities fraud. The lawsuit claims that Agenus made misrepresentations about its investigational therapy for metastatic colorectal cancer during the specified class period. Investors who purchased shares between January 23, 2023, and July 17, 2024, are encouraged to consider their legal rights. The deadline to file as a lead plaintiff in the case is November 5, 2024.

Market Sentiment Analysis

CONCERNS & RISKS

  • A class action lawsuit has been filed against Agenus for alleged securities fraud.
  • The lawsuit claims misrepresentation regarding the development of a therapy for metastatic colorectal cancer.
  • Shareholders have the opportunity to recover losses, but it indicates financial distress for the company.

Full Press Release Details

NEW YORK, Sept. 16, 2024 (GLOBE NEWSWIRE) -- Bernstein Liebhard LLP:
Do you, or did you, own shares of Agenus Inc. (NASDAQ: AGEN)?
Did you purchase your shares between January 23, 2023 and July 17, 2024, inclusive?
Did you lose money in your investment in Agenus Inc.?
Do you want to discuss your rights?
Bernstein Liebhard LLP, a nationally acclaimed investor rights law firm, reminds Agenus Inc. (“Agenus” or the “Company”) (NASDAQ: AGEN) investors of an upcoming deadline involving a securities fraud class action lawsuit commenced against the Company.
If you purchased or acquired Agenus securities, and/or would like to discuss your legal rights and options please visit Agenus Inc. Shareholder Class Action Lawsuit or contact Investor Relations Manager Peter Allocco at (212) 951-2030 or pallocco@bernlieb.com.
A lawsuit was filed in the United States District Court for the District of Massachusetts on behalf of investors who purchased or acquired the securities of Agenus between January 23, 2023 and July 17, 2024, inclusive (the “Class Period”)., alleging violations of the Securities Exchange Act of 1934 against the Company and certain of its senior officers.
According to the lawsuit, Agenus made misrepresentations concerning the development of the Company’s investigational therapy for the treatment of patients with metastatic colorectal cancer.
If you wish to serve as lead plaintiff for the Class, you must file papers by November 5, 2024. A lead plaintiff is a representative party acting on other class members’ behalf in directing the litigation. Your ability to share in any recovery doesn’t require that you serve as lead plaintiff. If you choose to take no action, you may remain an absent class member.
All representation is on a contingency fee basis. Shareholders pay no fees or expenses.
Since 1993, Bernstein Liebhard LLP has recovered over $3.5 billion for its clients. In addition to representing individual investors, the Firm has been retained by some of the largest public and private pension funds in the country to monitor their assets and pursue litigation on their behalf. As a result of its success litigating hundreds of class actions, the Firm has been named to The National Law Journal’s “Plaintiffs’ Hot List” thirteen times and listed in The Legal 500 for sixteen consecutive years.
ATTORNEY ADVERTISING. © 2024 Bernstein Liebhard LLP. The law firm responsible for this advertisement is Bernstein Liebhard LLP, 10 East 40th Street, New York, New York 10016, (212) 779-1414. Prior results do not guarantee or predict a similar outcome with respect to any future matter.
Contact Information:
Investor Relations Manager
Bernstein Liebhard LLP

Tags

class action lawsuit

Frequently Asked Questions

Who is involved in the Agenus class action lawsuit?

The lawsuit involves investors who purchased Agenus Inc. shares from January 23, 2023, to July 17, 2024.

What is the deadline for filing as lead plaintiff?

To serve as lead plaintiff, you must file paperwork by November 5, 2024.

What does the lawsuit allege against Agenus?

It alleges misrepresentations regarding their investigational therapy for metastatic colorectal cancer.

Are there any fees for participating in the lawsuit?

No fees or expenses are charged; all representation is on a contingency fee basis.

How has Bernstein Liebhard LLP performed historically?

The firm has recovered over $3.5 billion for clients and is recognized for its litigation success.

Last updated: Sep 16, 2024